Chemotherapy compared with biochemotherapy for the treatment of metastatic melanoma: A meta-analysis of 18 trials involving 2,621 patients

Journal of Clinical Oncology

Volumn 25, Issue 34, 2007, Pages 5426-5434

  Ives, Natalie J ^a   Stowe, Rebecca L ^a   Lorigan, Paul ^a   Wheatley, Keith ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ALPHA2A INTERFERON; ALPHA2B INTERFERON; ALPHAN1 INTERFERON; ANTINEOPLASTIC AGENT; ARANOZA; CARMUSTINE; CISPLATIN; DACARBAZINE; INTERLEUKIN 2; TAMOXIFEN; TEMOZOLOMIDE; UNCLASSIFIED DRUG; VINBLASTINE; VINDESINE;

ARTICLE; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CLINICAL EVALUATION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; DISEASE COURSE; DRUG EFFECT; DRUG WITHDRAWAL; HUMAN; LEUKOPENIA; LOW DRUG DOSE; MELANOMA; META ANALYSIS; METASTASIS; MONOTHERAPY; NEUTROPENIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HUMANS; INTERFERON-ALPHA; INTERLEUKIN-2; MELANOMA; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 36849061558     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.12.0253     Document Type: Article

References (43)

1. Department of Health: Compendium of Clinical and Health Indicators. National Centre for Health Outcomes Development, 2002
2. Balch CM, Buzaid AC, Soong SJ, et al: Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 19:3635-3648, 2001
3. Middleton MR, Grob JJ, Aaronson N, et al: Randomised phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic melanoma. J Clin Oncol 18: 158-166, 2000
4. Bedikian A, Millward M, Pehamberger H, et al: Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: The Oblimersen Melanoma Study Group. J Clin Oncol 24:4738-4745, 2006
5. Creagan ET, Ahmann DL, Frytak S, et al: Phase II trials of recombinant leukocyte A interferon in disseminated malignant melanoma: Results in 96 patients. Cancer Treat Rep 70:619-624, 1986
6. Kirkwood J, Ernstoff M: Potential applications of the interferons in oncology: Lessons drawn from studies of human melanoma. Semin Oncol 13:48-56, 1986 (suppl)
7. Moschos SJ, Edington HD, Land SR, et al: Neoadjuvant treatment of regional stage IIIB melanoma with high-dose interferon alpha-2b induces objective tumor regression in association with modulation of tumor infiltrating host cellular immune responses. J Clin Oncol 24:3164-3171, 2006
8. Agarwala SS, Glaspy J, O'Day SJ, et al: Results from a randomized phase III study comparing combined treatment with histamine dihydrochloride plus interleukin-2 versus interleukin-2 alone in patients with metastatic melanoma. J Clin Oncol 20:125-133, 2002
9. Atkins MB, Lotze MT, Dutcher JP, et al: High dose recombinant interleukin-2 therapy for patients with metastatic melanoma: Analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 17: 2105-2116, 1999
10. Keilholz U, Conradt C, Legha SS, et al: Results of interleukin-2-based treatment in advanced melanoma: A case record-based analysis of 631 patients. J Clin Oncol 16:2921-2929, 1998
11. Dickersin K, Scherer R, Lefebvre C: Identifying relevant studies for systematic reviews. BMJ 309:1286-1291, 1994
12. Mantel N, Haenszel W: Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22:719-748, 1959
13. Peto R, Pike MC, Armitage P, et al: Design and analysis of randomized clinical trials requiring prolonged observation of each patient: II, analysis and examples. Br J Cancer 35:1-39, 1977
14. Early Breast Cancer Trialists' Collaborative Group: Treatment of Early Breast Cancer, Vol 1: Worldwide Evidence 1985-1990. Oxford, United Kingdom, Oxford University Press, 1990
15. Parmar M, Torri V, Stewart L: Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 17:2815-2834, 1998
16. Fleiss JL: The statistical basis of metaanalysis. Stat Methods Med Res 2:121-145, 1993
17. Kirkwood JM, Ernstoff MS, Giuliano A, et al: Interferon α-2a and dacarbazine in melanoma. J Natl Cancer Inst 82:1062-1063, 1990
18. Galvez CA, Bonamassa M: Advanced malignant melanoma: DTIC plus rIFN-alfa-2b vs DTIC alone. Eur J Cancer 27:s155, 1991 (suppl 2; abstr 932)
19. Thomson DB, Adena M, McLeod RC, et al: Interferon-α2a does not improve response or survival when combined with dacarbazine in metastatic malignant melanoma: Results of a multi-institutional Australian randomized trial. Melanoma Res 3:133-138, 1993
20. Bajetta E, Di Leo A, Zampino MG, et al: Multicenter randomized trial of dacarbazine alone or in combination with two different doses and schedules of interferon alpha-2a in the treatment of advanced melanoma. J Clin Oncol 12:806-811, 1994
21. Vorobiof DA, Bezwoda WR: A randomised trial of vindesine plus interferon-α2b compared with interferon-α2b or vindesine alone in the treatment of advanced malignant melanoma. Eur J Cancer 30A: 797-800, 1994
22. Falkson CI: Experience with interferon alpha 2b combined with dacarbazine in the treatment of metastatic malignant melanoma. Med Oncol 12:35-40, 1995
23. Falkson CI, Ibrahim J, Kirkwood JM, et al: Phase III trial of dacarbazine versus dacarbazine with interferon alpha-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon alpha-2b and tamoxifen in patients with metastatic malignant melanoma: An Eastern Cooperative Oncology Group study. J Clin Oncol 16:1743-1751, 1998
24. 1 (IFN) for advanced malignant melanoma: A randomized pilot phase III study. Gan To Kagaku Ryoho 27:310-314, 2000 (suppl 2)
25. Young AM, Marsden J, Goodman A, et al: Prospective randomized comparison of dacarbazine (DTIC) versus DTIC plus interferon-alpha (IFN-alpha) in metastatic melanoma. Clin Oncol (R Coll Radiol) 13:458-465, 2001
26. Danson S, Lorigan P, Arance A, et al: Randomised phase II study of temozolomide given every 8 hours or daily with either interferon alpha-2b or thalidomide in metastatic malignant melanoma. J Clin Oncol 21:2551-2557, 2003
27. Kaufmann R, Spieth K, Leiter U, et al: Temozolomide in combination with interferon-alpha versus temozolomide alone in patients with advanced metastatic melanoma: A randomized, phase III, multicenter study from the Dermatologic Cooperative Oncology Group. J Clin Oncol 23:9001-9007, 2005
28. Johnston SRD, Constenla DO, Moore J, et al: Randomized phase II trial of BCDT [carmustine (BCNU), cisplatin, dacarbazine (DTIC) and tamoxifen] with or without interferon alpha (IFN-α) and interleukin (IL-2) in patients with metastatic melanoma. Br J Cancer 77:1280-1286, 1998
29. Rosenberg SA, Yang JC, Schwartzentruber DJ, et al: Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alpha-2b. J Clin Oncol 17:968-975, 1999
30. Atzpodien J, Neuber K, Kamanabrou D, et al: Combination chemotherapy with or without sc IL-2 and IFN-alpha: Results of a prospectively randomized trial of the Cooperative Advanced Malignant Melanoma Chemoimmunotherapy group (ACIMM). Br J Cancer 86:179-184, 2002
31. Ridolfi R, Chiarion-Sileni V, Guida M, et al: Cisplatin, dacarbazine with or without subcutaneous interleukin-2, and interferon alfa-2b in advanced melanoma outpatients: Results from an Italian multicenter phase III randomized clinical trial. J Clin Oncol 20:1600-1607, 2002
32. Eton O, Legha SS, Bedikian AY, et al: Sequential biochemotherapy versus chemotherapy for metastatic melanoma: Results from a phase III randomized trial. J Clin Oncol 20:2045-2052, 2002
33. Atkins MB, Lee S, Flaherty LE, et al: A prospective randomized phase III trial of concurrent biochemotherapy (BCT) with cisplatin, vinblastine, dacarbazine (CVD), IL-2 and interferon alpha-2b (IFN) versus CVD alone in patients with metastatic melanoma (E3695): An ECOG-coordinated intergroup trial. Proc Am Soc Clin Oncol 22:708, 2003 (abstr 2847)
34. Atkins MB, Lee S, Flaherty LE, et al: A prospective randomized phase III trial of concurrent biochemotherapy (BCT) with cisplatin, vinblastine, dacarbazine (CVD), IL-2 and interferon α-2b (IFN) versus CVD alone in patients with metastatic melanoma (E3695): An ECOG-coordinated intergroup trial. Presented at the 39th Annual Meeting of the American Society of Clinical Oncology, May 31-June 3, 2003, Chicago, IL
35. Del Vecchio M, Bajetta E, Vitali M, et al: Multicenter phase III randomized trial of cisplatin, vindesine and dacarbazine (CVD) versus CVD plus subcutaneous (sc) interleukin-2 (IL-2) and interferon-alpha-2b (IFN) in metastatic melanoma patients (pts). Proc Am Soc Clin Oncol 22:709, 2003 (abstr 2849)
36. Del Vecchio M: Multicenter phase III randomized trial of CVD vs CVD plus biotherapy in metastatic melanoma. Presented at the 39th annual meeting of the American Society of Clinical Oncology, May 31-June 3, 2003, Chicago, IL
37. WHO: WHO Handbook for Reporting Results of Cancer Treatment. WHO offset publication No. 48. Geneva, Switzerland, World Health Organization, 1979, pp 22-30
38. Collins R, Peto R, Gray R, et al: Large-scale randomized evidence: Trials and overviews, in Weatherall D, Ledingham JGG, Warrell DA (ed): Oxford Textbook of Medicine, Vol 1. Oxford, United Kingdom, Oxford University Press, 1996, pp 21-32
39. Keilholz U, Punt CJ, Gore M, et al: Dacarbazine, cisplatin and IFN-alpha-2b with or without IL-2 in metastatic melanoma: A randomized phase III trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma Group. J Clin Oncol 23:6747-6755, 2005
40. Luikart SD, Kennealey GT, Kirkwood JM: Randomised phase III trial of vinblastine, bleomycin and cis-dichlorodiammine-platinum versus dacarbazine in malignant melanoma. J Clin Oncol 2:164-168, 1984
41. Chapman PB, Einhorn LH, Meyers ML, et al: Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol 17:2745-2751, 1999
42. Middleton M, Lorigan P, Owen J, et al: A randomized phase III study comparing dacarbazine, BCNU, cisplatin and tamoxifen with dacarbazine and interferon in advanced melanoma. Br J Cancer 82: 1158-1162, 2000
43. Sasse A, Sasse E, Clark L, et al: Chemoimmunotherapy versus chemotherapy for metastatic malignant melanoma. Cochrane Database Syst Rev, 2007